Berger Montague Investigates Potential Securities Fraud Claims Against Athira Pharma, Inc. (ATHA); Lead Plaintiff Deadline is August 24, 2021

Philadelphia, Pennsylvania--(Newsfile Corp. - July 3, 2021) - Berger Montague is investigating potential securities fraud claims against Athira Pharma, Inc. ("Athira" or the "Company"). The Firm is investigating these allegations on behalf of investors who purchased Athira securities (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 (the "Class Period"), including shares purchased on or traceable to the Company's initial public offering in September 2020.

If you purchased Athira securities during the Class Period and are interested in learning more about Berger Montague's investigation, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Donnell Much at dmuch@bm.net or (215) 875-4667, or submit the contact form on www.bergermontague.com/athira.

Athira, based in Washington, is a biopharma company developing treatments for neurodegeneration, such as Alzheimer's disease. Since going public in September 2020, Athira and senior management have repeatedly emphasized the importance of CEO Leen Kawas' doctoral research to the company's product candidates.

According to recently filed lawsuits, the Company and the underwriters of its IPO failed to disclose to investors that research conducted by Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including manipulation of key data.

Investors began to learn the truth on June 17, 2021, when the Company announced that Kawas had been placed on leave pending a review of accusations that, while a doctoral student at Washington State University, Kawas altered images in four separate papers, calling into question research upon which Athira's products are based. On this news, Athira shares declined $7.09 per share, or 39%, to close at $11.15 per share on June 18, 2021.

Whistleblowers: Anyone with non-public information regarding Athira is encouraged to confidentially assist Berger Montague's investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.

Berger Montague, with offices in Philadelphia, Minneapolis, Washington, D.C., and San Diego, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bm.net

Donnell Much, Associate
Berger Montague
(215) 875-4667
dmuch@bm.net

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/89301